Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Diabetes Investig ; 14(10): 1183-1186, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37395013

RESUMO

The relationship between urinary endothelial growth factor (uEGF) and cardiovascular autonomic neuropathy (CAN) in adults with type 1 diabetes was evaluated. uEGF levels at baseline and standardized CAN measures were collected at baseline and annually for 3 years for type 1 diabetes adults. Linear regression analysis and linear mixed effects model were used for analysis. In this cohort (n = 44, 59% women, mean ± standard deviation age 34 ± 13 years and diabetes duration 14 ± 6 years), lower baseline uEGF levels correlated with lower baseline expiration : inspiration ratios (P = 0.03) and greater annual declines in Valsalva ratios (P = 0.02) in the unadjusted model, and correlated with lower low-frequency power : high-frequency power ratios (P = 0.01) and greater annual changes in low-frequency power : high-frequency power ratios (P = 0.01) after adjustment for age, sex, body mass index, and hemoglobin A1C. In conclusion, baseline uEGF levels correlate to baseline and longitudinal changes in CAN indices. A large-scale, long-term study is needed to validate uEGF as a reliable CAN biomarker.


Assuntos
Doenças do Sistema Nervoso Autônomo , Diabetes Mellitus Tipo 1 , Neuropatias Diabéticas , Humanos , Adulto , Feminino , Adulto Jovem , Pessoa de Meia-Idade , Masculino , Fator de Crescimento Epidérmico/urina , Diabetes Mellitus Tipo 1/complicações , Sistema Nervoso Autônomo , Biomarcadores/urina , Doenças do Sistema Nervoso Autônomo/complicações , Doenças do Sistema Nervoso Autônomo/diagnóstico , Neuropatias Diabéticas/etiologia
2.
Kidney Int ; 103(3): 565-579, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36442540

RESUMO

The diagnosis of nephrotic syndrome relies on clinical presentation and descriptive patterns of injury on kidney biopsies, but not specific to underlying pathobiology. Consequently, there are variable rates of progression and response to therapy within diagnoses. Here, an unbiased transcriptomic-driven approach was used to identify molecular pathways which are shared by subgroups of patients with either minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). Kidney tissue transcriptomic profile-based clustering identified three patient subgroups with shared molecular signatures across independent, North American, European, and African cohorts. One subgroup had significantly greater disease progression (Hazard Ratio 5.2) which persisted after adjusting for diagnosis and clinical measures (Hazard Ratio 3.8). Inclusion in this subgroup was retained even when clustering was limited to those with less than 25% interstitial fibrosis. The molecular profile of this subgroup was largely consistent with tumor necrosis factor (TNF) pathway activation. Two TNF pathway urine markers were identified, tissue inhibitor of metalloproteinases-1 (TIMP-1) and monocyte chemoattractant protein-1 (MCP-1), that could be used to predict an individual's TNF pathway activation score. Kidney organoids and single-nucleus RNA-sequencing of participant kidney biopsies, validated TNF-dependent increases in pathway activation score, transcript and protein levels of TIMP-1 and MCP-1, in resident kidney cells. Thus, molecular profiling identified a subgroup of patients with either MCD or FSGS who shared kidney TNF pathway activation and poor outcomes. A clinical trial testing targeted therapies in patients selected using urinary markers of TNF pathway activation is ongoing.


Assuntos
Glomerulosclerose Segmentar e Focal , Nefrologia , Nefrose Lipoide , Síndrome Nefrótica , Humanos , Glomerulosclerose Segmentar e Focal/patologia , Nefrose Lipoide/diagnóstico , Inibidor Tecidual de Metaloproteinase-1 , Síndrome Nefrótica/diagnóstico , Fatores de Necrose Tumoral/uso terapêutico
3.
Diabetes ; 71(12): 2664-2676, 2022 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-36331122

RESUMO

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD). Prognostic biomarkers reflective of underlying molecular mechanisms are critically needed for effective management of DKD. A three-marker panel was derived from a proteomics analysis of plasma samples by an unbiased machine learning approach from participants (N = 58) in the Clinical Phenotyping and Resource Biobank study. In combination with standard clinical parameters, this panel improved prediction of the composite outcome of ESKD or a 40% decline in glomerular filtration rate. The panel was validated in an independent group (N = 68), who also had kidney transcriptomic profiles. One marker, plasma angiopoietin 2 (ANGPT2), was significantly associated with outcomes in cohorts from the Cardiovascular Health Study (N = 3,183) and the Chinese Cohort Study of Chronic Kidney Disease (N = 210). Glomerular transcriptional angiopoietin/Tie (ANG-TIE) pathway scores, derived from the expression of 154 ANG-TIE signaling mediators, correlated positively with plasma ANGPT2 levels and kidney outcomes. Higher receptor expression in glomeruli and higher ANG-TIE pathway scores in endothelial cells corroborated potential functional effects in the kidney from elevated plasma ANGPT2 levels. Our work suggests that ANGPT2 is a promising prognostic endothelial biomarker with likely functional impact on glomerular pathogenesis in DKD.


Assuntos
Diabetes Mellitus , Nefropatias Diabéticas , Falência Renal Crônica , Humanos , Angiopoietina-1/genética , Receptor TIE-2/genética , Nefropatias Diabéticas/genética , Estudos de Coortes , Células Endoteliais , Angiopoietina-2/genética , Angiopoietinas , Transdução de Sinais , Biomarcadores , Progressão da Doença
4.
J Consum Aff ; 56(1): 141-157, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35603321

RESUMO

The Coronavirus (COVID-19) pandemic reduced real and perceived access to healthcare services, exacerbating pandemic fear, and thus influencing consumers' adoption of preventative health behaviors. Extending the EHBM, results from two studies show that perceived access to health services and pandemic fear impact an individual's general and COVID-preventative health behaviors. High perceived access reduces pandemic fear through its buffering effects on perceived health vulnerability and pandemic-related health system concern, especially with telehealth usage during the pandemic. While pandemic fear motivates COVID-19 vaccination, pandemic fear reduces personal preventative health behavior (e.g., healthy eating, exercising) and has little effect on personal COVID-preventative behaviors (e.g., wearing a mask, social distancing) when individuals perceive high pandemic-related control. Moreover, the fear-behavior link does not hold for preventative health visits; instead, perceived access directly promotes preventative visits and screening. This research informs public health stakeholders' communication, education, and resource allocation during health crises like the COVID-19 pandemic.

5.
Kidney Int ; 100(1): 107-121, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33675846

RESUMO

Since failed resolution of inflammation is a major contributor to the progression of diabetic nephropathy, identifying endogenously generated molecules that promote the physiological resolution of inflammation may be a promising therapeutic approach for this disease. Annexin A1 (ANXA1), as an endogenous mediator, plays an important role in resolving inflammation. Whether ANXA1 could affect established diabetic nephropathy through modulating inflammatory states remains largely unknown. In the current study, we found that in patients with diabetic nephropathy, the levels of ANXA1 were upregulated in kidneys, and correlated with kidney function as well as kidney outcomes. Therefore, the role of endogenous ANXA1 in mouse models of diabetic nephropathy was further evaluated. ANXA1 deficiency exacerbated kidney injuries, exhibiting more severe albuminuria, mesangial matrix expansion, tubulointerstitial lesions, kidney inflammation and fibrosis in high fat diet/streptozotocin-induced-diabetic mice. Consistently, ANXA1 overexpression ameliorated kidney injuries in mice with diabetic nephropathy. Additionally, we found Ac2-26 (an ANXA1 mimetic peptide) had therapeutic potential for alleviating kidney injuries in db/db mice and diabetic Anxa1 knockout mice. Mechanistic studies demonstrated that intracellular ANXA1 bound to the transcription factor NF-κB p65 subunit, inhibiting its activation thereby modulating the inflammatory state. Thus, our data indicate that ANXA1 may be a promising therapeutic approach to treating and reversing diabetic nephropathy.


Assuntos
Anexina A1 , Diabetes Mellitus Experimental , Nefropatias Diabéticas , Animais , Anexina A1/genética , Diabetes Mellitus Experimental/complicações , Humanos , Inflamação , Rim , Camundongos
6.
Am J Orthopsychiatry ; 72(2): 182-93, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15792058
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...